Rita Nanda, MD

Rita Nanda, MD, discusses the IMpower130 trial in patients with metastatic triple-negative breast cancer who express PD-L1.

Rita Nanda, MD, assistant professor of Medicine, assistant director, Breast Medical Oncology, discusses results from I-SPY 2, which explored pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer. 

Rita Nanda, MD, assistant professor of Medicine, associate director, Breast Medical Oncology, The University of Chicago Medicine, discusses the treatment of metastatic triple-negative breast cancer (TNBC).